Vir Biotechnology, Inc. (VIR)
After hours:
| Previous close | 29.45 |
| Open | 29.05 |
| Bid | 27.02 x 1000 |
| Ask | 27.14 x 900 |
| Day's range | 27.04 - 29.00 |
| 52-week range | 18.05 - 34.63 |
| Volume | |
| Avg. volume | 795,605 |
| Market cap | 3.603B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 3.25 |
| EPS (TTM) | 8.32 |
| Earnings date | 22 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.43 |
- GlobeNewswire
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors – SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company’s Board of Directors h
- Zacks
Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Motley Fool
2 Stocks That Could Turn $100 Into $1,000 by 2028
Doing so requires a substantial compound annual growth rate (CAGR) exceeding 58%. You're not likely to see such a rate among value stocks, which for all their consistency rarely grow at that pace. Two companies where I see that kind of progress over the next five years are Vir Biotechnology (NASDAQ: VIR) and Albemarle (NYSE: ALB).
